KRYSTAL BIOTECH (NASDAQ:KRYS) Director Daniel Janney purchased 200,000 shares of the firm’s stock in a transaction on Friday, September 22nd. The stock was bought at an average price of $10.00 per share, with a total value of $2,000,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

KRYSTAL BIOTECH (NASDAQ:KRYS) opened at 10.049 on Thursday. The stock’s market cap is $96.90 million. KRYSTAL BIOTECH has a 1-year low of $10.00 and a 1-year high of $11.31.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at


Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.

Receive News & Stock Ratings for KRYSTAL BIOTECH Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KRYSTAL BIOTECH and related stocks with our FREE daily email newsletter.